Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience

Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience

Abstract Introduction Relapse is common after treatment discontinuation for patients with moderate-to-severe psoriasis. The objective of this study was to understand the remission duration and long-term outcomes in psoriasis patients after biologic withdrawal. Methods We retrospectively included the...

Full description

Bibliographic Details
Main Authors: Yi-Wei Huang, Tsen-Fang Tsai
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-07-01
Series:Dermatology and Therapy
Subjects:
Biologic
Discontinuation
Early
Outcome
Predictor
Psoriasis
Online Access:http://link.springer.com/article/10.1007/s13555-019-0310-5

Internet

http://link.springer.com/article/10.1007/s13555-019-0310-5

Similar Items